Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Uterine Cervical Neoplasms 4Prostatic Neoplasms 4Uveal Melanoma 1Radiation Injuries 1Prostatic Diseases 1Melanoma 1Locally Advanced Cervical Carcinoma 1Glioblastoma 1Cervical Adenocarcinoma 1Carcinoma, Ductal, Breast 1Breast Neoplasms 1Brain Neoplasms 1Adenocarcinoma 1

Interventions

Gemcitabine 8pembrolizumab 5Paclitaxel 4Capecitabine 4Albumin-Bound Paclitaxel 4Nivolumab 3Fluorouracil 3Cyclophosphamide 3Carboplatin 3sargramostim 2poly ICLC 2fludarabine 2Prednisone 2Oxaliplatin 2Irinotecan 2Hydroxychloroquine 2Erlotinib Hydrochloride 2Dexamethasone 2Cisplatin 2130-nm albumin-bound paclitaxel 2temsirolimus 1tegafur-gimeracil-oteracil 1spartalizumab 1sintilimab 1rucaparib 1resiquimod 1repotrectinib 1regorafenib 1pralsetinib 1olaparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Adenocarcinoma × Brachytherapy × Clear all
NCT07182279 2026-03-09

Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer

The Methodist Hospital Research Institute

Phase 1/2 Recruiting
29 enrolled
Genitourinary

Adenocarcinoma, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡